Hamada Y, Odagaki Y, Sakakibara F, Naruse K, Koh N, Hotta N
Third Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Life Sci. 1995;57(1):23-9. doi: 10.1016/0024-3205(95)00239-3.
Fructose 3-phosphate and sorbitol 3-phosphate are novel metabolites that have been shown to associate with the polyol pathway in animal experiments. Fructose 3-phosphate is of particular interest because of its potent glycation capability as compared with other glycolytic intermediates, e.g., fructose. We observed the effects of treatment with epalrestat, an aldose reductase inhibitor, on their concentrations in erythrocytes from diabetic patients. The levels of both metabolites were significantly higher in diabetic patients than in non-diabetic subjects. A group of patients who had been treated with epalrestat showed significantly lower levels of both metabolites as compared with those untreated. A treatment of three patients with epalrestat for one month resulted in obvious decreases in their concentrations. The results suggest a possible explanation for the preventive effect of an aldose reductase inhibitor on nonenzymatic glycation.
3-磷酸果糖和3-磷酸山梨醇是新发现的代谢产物，在动物实验中已显示它们与多元醇途径相关。3-磷酸果糖特别引人关注，因为与其他糖酵解中间产物（如果糖）相比，它具有很强的糖化能力。我们观察了醛糖还原酶抑制剂依帕司他对糖尿病患者红细胞中这些代谢产物浓度的影响。糖尿病患者体内这两种代谢产物的水平均显著高于非糖尿病受试者。与未接受治疗的患者相比，一组接受依帕司他治疗的患者体内这两种代谢产物的水平均显著降低。对三名患者使用依帕司他治疗一个月后，其浓度明显下降。这些结果为醛糖还原酶抑制剂对非酶糖化的预防作用提供了一种可能的解释。
